Intest Res 2018; 16(3): 393-399
Immunohistochemical differentiation between chronic enteropathy associated with SLCO2A1 gene and other inflammatory bowel diseases
Satoko Yamaguchi1*, Shunichi Yanai1*, Shotaro Nakamura1, Keisuke Kawasaki1, Makoto Eizuka2, Noriyuki Uesugi2, Tamotsu Sugai2, Junji Umeno3, Motohiro Esaki3, Takayuki Matsumoto1
1Division of Gastroenterology, Department of Internal Medicine and 2Division of Molecular Diagnostic Pathology, Department of Pathology, Iwate Medical University School of Medicine, Morioka, 3Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Correspondence to: Shotaro Nakamura, Division of Gastroenterology, Department of Internal Medicine, Iwate Medical University School of Medicine, Uchimaru 19-1, Morioka 020-8505, Japan. Tel: +81-19-651-5111 (ext. 2311/2314), Fax: +81-19-652-6664, E-mail:
*These authors contributed equally to this study.
Received: October 5, 2017; Revised: December 2, 2017; Accepted: December 29, 2017; Published online: March 6, 2018.
© Korean Association for the Study of Intestinal Diseases. All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background/Aims: We recently identified recessive mutations in the solute carrier organic anion transporter family member 2A1 gene (SLCO2A1) as causative variants of chronic enteropathy associated with SLCO2A1 (CEAS). The aim of this study was to evaluate SLCO2A1 protein expression in the intestinal tissues of patients with CEAS, intestinal Behçet’s disease (BD), simple ulcer (SU), and Crohn’s disease (CD). Methods: Immunohistochemical staining using a polyclonal anti-SLCO2A1 antibody was performed on the resected intestinal specimens from 13 cases of CD, 9 cases of intestinal BD/SU, and 3 cases of CEAS. The extent of SLCO2A1 expression was determined by counting positively-staining vascular endothelial cells and scored as 0 (no cells), 1 (1%−30% cells), 2 (31%−60%), or 3 (>60%). The intensity of SLCO2A1 expression was scored either as 0 (negative), 1 (intermediate), or 2 (strong). The extent score and intensity score were summed for the final score of 0, 2, 3, 4, or 5. Results: SLCO2A1 protein expression was observed in 1 of 3 cases of CEAS (33%), all 13 cases of CD (100%), and all 9 cases of BD/SU (100%). The mean final expression scores of CEAS, CD, and BD/SU were 1.6 (range, 0−5), 4.8 (range, 4−5), and 4.3 (range, 4−5), respectively. The final expression score in CEAS was significantly lower than in CD (P=0.03). Conclusions: Immunohistochemical staining of the SLCO2A1 protein is considered useful to distinguish CEAS from other inflammatory bowel diseases.
Keywords: SLCO2A1; Chronic enteropathy; Crohn disease; Behcet syndrome; Immunohistochemistry

This Article



Official Journal of

Indexed/Covered by